661 related articles for article (PubMed ID: 8555184)
1. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
2. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
[TBL] [Abstract][Full Text] [Related]
3. Subcellular localization of PP5/TFPI-2 in human placenta: a possible role of PP5/TFPI-2 as an anti-coagulant on the surface of syncytiotrophoblasts.
Udagawa K; Yasumitsu H; Esaki M; Sawada H; Nagashima Y; Aoki I; Jin M; Miyagi E; Nakazawa T; Hirahara F; Miyazaki K; Miyagi Y
Placenta; 2002; 23(2-3):145-53. PubMed ID: 11945080
[TBL] [Abstract][Full Text] [Related]
4. Effect of leukocyte proteinases on tissue factor pathway inhibitor.
Petersen LC; Bjørn SE; Nordfang O
Thromb Haemost; 1992 May; 67(5):537-41. PubMed ID: 1519213
[TBL] [Abstract][Full Text] [Related]
5. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
Lindhout T; Franssen J; Willems G
Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
[TBL] [Abstract][Full Text] [Related]
7. Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2.
Rao CN; Reddy P; Reeder DJ; Liu Y; Stack SM; Kisiel W; Woodley DT
Biochem Biophys Res Commun; 2000 Oct; 276(3):1286-94. PubMed ID: 11027624
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.
Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ
Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor.
Sprecher CA; Kisiel W; Mathewes S; Foster DC
Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3353-7. PubMed ID: 8159751
[TBL] [Abstract][Full Text] [Related]
10. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
Zhang E; St Charles R; Tulinsky A
J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
[TBL] [Abstract][Full Text] [Related]
11. The lipoprotein-associated coagulation inhibitor.
Broze GJ; Girard TJ; Novotny WF
Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
[TBL] [Abstract][Full Text] [Related]
12. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
[TBL] [Abstract][Full Text] [Related]
13. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
14. Characterization of placental bikunin, a novel human serine protease inhibitor.
Delaria KA; Muller DK; Marlor CW; Brown JE; Das RC; Roczniak SO; Tamburini PP
J Biol Chem; 1997 May; 272(18):12209-14. PubMed ID: 9115295
[TBL] [Abstract][Full Text] [Related]
15. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
18. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Hamamoto T; Kisiel W
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions.
Pedersen AH; Nordfang O; Norris F; Wiberg FC; Christensen PM; Moeller KB; Meidahl-Pedersen J; Beck TC; Norris K; Hedner U
J Biol Chem; 1990 Oct; 265(28):16786-93. PubMed ID: 2211593
[TBL] [Abstract][Full Text] [Related]
20. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]